Contrast Agents - Articles

Sort by: Newest Most Comments Relevance

MRI contrast agents change stem cell proliferation by David Granovsky Posted Mon 14 Feb 2011 1:19pm MRI contrast agents change stem cell proliferation Tampa, Fla. (Nov. 01, 2010) – When researchers tested three different labeling agents on three different stem cell populations to determine what effect the labeling agents had on stem cell phenotype, biological behavior and migration abilities, they found changes in stem cell proliferation depending Read on »

Superior Method of Preparing Dendrimers for Use as Magnetic Resonance Imaging (MRI) Contrast Agents by nih.gov Posted Mon 10 Aug 2009 5:00pm Description of Invention: There is a need to develop more efficient gadolinium-containing (Gd) contrast agents for magnetic resonance imaging (MRI) as the small molecules presently used clinically have the disadvantage of being rapidly cleared from circulation and excreted by the kidneys. Dendrimer-based macromolecular MRI contrast agents Read on »

Microfabricated Particles Useful as MRI Contrast Agents by nih.gov Posted Sun 14 Mar 2010 5:00pm Description of Invention: MRI contrast agents are versatile yet lack the sensitivity and multiplexing capabilities of optical agents. Available for licensing is an invention pertaining to microfabricated structures that can be used as MRI contrast agents with enhanced functionality or as micro-RFID (radio-frequency identification) tags Read on »

FDA Drug Safety Communication: New warnings for using gadolinium-based contrast agents in patients with kidney dysfunction by FDA Posted Thu 09 Sep 2010 9:56am Gadolinium Based Contrast Agents Safety Announcement [09-09-2010] The U.S. Food and Drug Administration (FDA) is requiring changes in the drug label for gadolinium-based contrast... to enhance the contrast agent's elimination from the body. The usefulness of hemodialysis in the prevention of NSF is unknown. Advise patients with kidney disease to contact Read on »

Gadolinium-based Contrast Agents: Class Labeling Change - Risk of Nephrogenic Systemic Fibrosis by FDA Posted Thu 09 Sep 2010 1:50pm changes in the professional labeling for gadolinium-based contrast agents (GBCAs) to minimize the risk of nephrogenic systemic fibrosis (NSF), a rare, but serious, condition... - Drug Safety Communication - FDA] [08/13/2009 - Q&As - FDA] Previous MedWatch Alert [06/08/2006 - Gadolinium-containing Contrast Agents for Magnetic Resonance Imaging (MRI Read on »

Important update on the MRI contrast agent gadolinium… by Margaret Patient Expert

Posted Mon 24 Jan 2011 5:41am is a commonly used gadolinium-containing contrast agent…It’s an easy read, so please check it out when you have a sec… This article reminded me of my December 13 2010 post, the one Read on »

What you should know about contrast media by ViaMedica Posted Fri 23 Oct 2009 10:06pm Read on »

MRI Contrast Media Eliminates NSF Cases by ViaMedica Posted Fri 23 Oct 2009 10:06pm Read on »

Trick Question Regarding Contrast-Induced Nephropathy by Matt S. Posted Fri 18 Jul 2008 12:00am Trick Question: Which would you imagine to be lower osmolarity between "low osmolar iv contrast" and "iso-osmolar iv contrast"? The answer is, for historical reasons, "iso-osmolar contrast." The increasing use of iv contrast agents led to the identification of contrast-induced nephropathy (CIN) as a major cause of in-hospital acute kidney Read on »

Mucin Binding Lectin Imaging Agents for Colonic Polyp Imaging by nih.gov Posted Fri 29 Feb 2008 4:00pm targeted with UEA-1 contrast agents. In one example, a computer tomography (CT) agent made from Iodine-127 (127I) labeled UEA-1 (I-UEA-1) and encapsulated into polymeric liposome nanoparticles was used to image murine colonic polyps. Ideally, the inventors envision a contrast agent that can be administered orally (e.g., liquid or pill form) and that would Read on »